Date & Time of Session - 2/13/26 - from 12:00 - 1:00PM
Overview
As β-lactam therapeutic drug monitoring (TDM) becomes incorporated into clinical practice at UK, a clear understanding of its evidence base is essential. Emerging evidence demonstrates substantial interpatient variability in β-lactam exposure, particularly in critically ill patients. This session will summarize the literature and available clinical data regarding β-lactam TDM. The intent is to align practice with current evidence while promoting safe and effective antibiotic use.
Objectives
Upon completion of this activity, participants will be able to:
1. Review the rationale for beta-lactam therapeutic drug monitoring (TDM)
2. Describe the evidence for establishment of pharmacokinetic/pharmacodynamic efficacy and safety targets
3. Evaluate literature and applicability of TDM to clinical practice
Target Audience
Pharmacists, residents, and students
Special Services
If you require special assistance to attend this event, please call Megan Russell at (304) 550-0896.
Speaker:
Christine Wu, PharmD
PGY2 Infectious Diseases Pharmacy Resident (Pediatric)
UK College of Pharmacy - Lexington, Kentucky
- 1.00 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-0000-25-046-L01-P
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.

Facebook
X
LinkedIn
Forward